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Abstract
Background and Objective For specific immunotherapy
to pollen allergy, a pre-seasonal start of treatment is rec-
ommended by international guidelines. In a placebo-con-
trolled clinical trial with adults, an intra-seasonal start of
therapy with the SQ-standardised grass allergy immuno-
therapy tablet (AIT) was well-tolerated. The objective of
our study was to investigate the feasibility of an intra-
seasonal start of grass AIT administered during routine
treatment by practising allergists.
Methods In a multicentre, prospective, open-label,
uncontrolled, non-interventional observational study, data
on routine treatment with grass AIT were recorded in
patients who started administration of tablets within the
2010 grass pollen season in Germany. Adverse events
(AEs) were recorded by the physician at visits for the first
administration in the clinic and at the end of the 1- to
3-month observation period. AEs and daily administration
of the tablet were recorded by the patients in diaries for the
first 14 days. Treatment satisfaction, global tolerability and
perceived effect of treatment were assessed by the patient
and physician at the end of the study.
Results A total of 662 patients were treated with 1 tablet
daily by 286 physicians. Grass AIT was started intra-season-
ally in 620 patients and post-season in 42. The average treat-
ment period was 51.6 days. AEs were recorded in 52.1 % of all
patients and in 35.6 % at first administration, with throat
irritation (21.3 %), paraesthesia oral (19.9 %), oral pruritus
(14.0 %) and ear pruritus (10.3 %) being the most frequent
AEs related to grass AIT. The intensity of the AEs was
assessed as mild or moderate in 42.1 % of patients and severe
in 8.0 %; AEs related to grass AIT were classified as serious in
two patients. Grass AIT was discontinued due to AEs in 7.7 %
of patients. Diaries were evaluable for 77.0 % of patients; the
average rate of patients with AEs decreased continuously
from 44.7 % (day 1) to 26.9 % (day 14) and the average daily
rate of patients who forgot to take their tablet was about 5 %.
Overall tolerability was assessed by 87.2 % of patients and
91.4 % physicians as ‘‘very good’’ or ‘‘good’’ and effective-
ness of treatment was assessed as ‘‘very good’’ or ‘‘good’’ in
81.4 % of patients and 85.8 % of physicians. More than 90 %
of patients and physicians were satisfied with the treatment.
Conclusion The tolerability data for an intra-seasonal
start of grass AIT during routine treatment confirm the
safety profile from the previous controlled trial. Tolera-
bility was assessed as good in combination with high sat-
isfaction with the treatment and compliance.
1 Introduction
Allergic rhinoconjunctivitis represents a global health
problem, affecting approximately one-quarter of the
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European population [1, 2]. Specific immunotherapy (SIT)
is the only treatment modality with the potential to alter the
natural course of the disease and offer sustained reductions
in symptoms after treatment discontinuation [3].
The first immunotherapies were administered subcuta-
neously by physicians (allergen injections), but today’s
treatments have been extended to sublingual administration
by daily drop-based formulations as well as to an allergy
immunotherapy tablet (AIT). Sublingual administration
offers several potential advantages compared with the
subcutaneous route, including increased convenience and
an improved tolerability profile [overcoming concerns
regarding systemic adverse events (AEs) associated with
subcutaneous administration] [1, 4, 5].
Grass AIT has been approved for marketing in several
European countries for the disease-modifying treatment of
grass pollen-induced rhinoconjunctivitis in adults and chil-
dren (5 years or older). The clinical efficacy and favourable
tolerability profile of grass AIT has been reported in a series
of randomised controlled trials in adults and children [6–15].
Furthermore, sustained clinical efficacy and disease modi-
fication 2 years after completion of 3 years of treatment with
grass AIT has recently been demonstrated in a double-blind,
multinational, placebo-controlled trial [16]. The most com-
mon AEs associated with grass AIT have been mild to
moderate local reactions in the mouth or throat (e.g. oral
pruritus), predominantly occurring after first administration
or during the initial treatment phase [6–13].
For initiation of SIT, patients are usually asked to return
after the grass pollen season when they are no longer exposed
to grass pollen. The possibility of intra-seasonal treatment
initiation may be of interest to patients and prescribing
physicians because allergy patients often first contact the
physician due to symptoms during the grass pollen season.
However, because patients may be less motivated to initiate
immunotherapy when symptoms decline after the grass
pollen season, treatment may not be started in a considerable
proportion of these patients. As a result, many of these
patients are likely to present again in the following season
with sub-optimally controlled symptoms.
In a multicentre, randomised, double-blind, placebo-
controlled phase III trial, intra-seasonal initiation of grass
AIT was associated with an immunomodulatory response in
terms of induction of immunoglobulin (Ig) E-blocking fac-
tor, specific IgE and specific IgG4. Furthermore, the intra-
seasonal-initiated therapy was generally well-tolerated [17].
Systematically recorded data on safety and tolerability
of the intra-seasonal start of grass AIT in real life are
needed to evaluate the benefit and risks in daily use.
The objective of our non-interventional, observational
study was, therefore, to investigate the feasibility of an
intra-seasonal start of grass AIT during routine adminis-
tration under real life conditions.
2 Methods
2.1 Study Design and Treatment
In this non-interventional, open-label, uncontrolled obser-
vational study the treatment of patients who started grass-
AIT administration within the summer grass pollen season
between June and August 2010 in Germany was planned to
be documented by 286 allergologically trained physicians
distributed across Germany.
For treatment with grass AIT GRAZAX (Phleum
pratense 75,000 SQ-T/2,800 BAU, ALK, Hørsholm,
Denmark) was applied.
Centres were asked to participate in the study according
to regional random lists of allergists applying SIT and were
asked to record data on two to three patients in consecutive
order, dependent on the patient’s willingness to participate
in the study, in order to avoid a selection bias. Physicians
were asked to document all patients who were potentially
eligible to be included in a patient log.
2.2 Participants
Data on patients with a diagnosis of grass pollen-induced
rhinitis and/or conjunctivitis (according to symptoms, skin
prick test or RAST) with or without asthma with clinically
relevant symptoms who had no contraindications to a
prescription of grass AIT according to the Summary of
Product Characteristics for GRAZAX [18] were eligible
to be documented in this study. Contraindications included
hypersensitivity to any of the excipients of the AIT,
malignancy or systemic diseases affecting the immune
system, e.g. autoimmune diseases, immune complex dis-
eases or immune deficiency diseases; inflammatory con-
ditions in the oral cavity with severe symptoms such as oral
lichen planus with ulcerations or severe oral mycosis; and
patients with uncontrolled or severe asthma (forced expi-
ratory volume in 1 second \70 % of predicted value after
adequate pharmacological treatment in adults and \80 %
in children). The study plan was approved by the Ethics
Committee of the Landesa¨rztekammer Baden-Wu¨rttem-
berg and patient consent for the collection of their data was
obtained.
2.3 Data Collection
The time schedule and the major observations of the study
are illustrated in Fig. 1.
At visit 1 (V1), when the patient was included in the
study, demographic data and data on the allergy history
including age at first appearance of symptoms, clinical
manifestation of the allergy (rhinitis/conjunctivitis/asthma/
atopic dermatitis), other allergies, the diagnostics performed,
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any previous treatment by SIT, and concomitant treatments
by SIT or other medications due to concomitant diseases
were recorded. Symptoms and medication use in the pre-
vious grass pollen season were recorded retrospectively.
Symptoms were recorded as nasal, ocular, bronchial and
skin symptoms assessed on a scale from 0 to 3 (no/mild/
moderate/severe) and the different types of symptomatic
medication that had been used (topical nasal and eye
drops/oral antihistamines/oral corticosteroids/bronchial
b-sympathomimetics/bronchial corticosteroids/other) were
recorded. The first administration of the grass AIT was
performed in the clinic, where an eventual anti-allergic pre-
medication was recorded as well as any AEs that occurred
while the patient was under observation for 30 min. An AE
was defined as any untoward medical occurrence in a
patient who was administered grass AIT and which did not
necessarily have a causal relationship with treatment. AEs
that were possibly related to treatment were classified as
adverse drug reactions (ADRs). For the first 2 weeks of
therapy, patients were asked to enter the administration of
the grass AIT and all AEs and the respective actions they
had taken (medication taken/physician contacted) in a
diary. AEs were specified by the physician in the case
report form (CRF) as diagnosis or description and assessed
by intensity (mild/moderate/severe), causality (possible/
unlikely), change of treatment (no change/interruption/
discontinuation), treatment by medication (yes/no), out-
come (recovered/improved/recovered with sequelae/not
recovered/fatal/unknown) and whether it was serious (yes/
no). An AE was assessed as severe when the event con-
siderably interfered with the patient’s daily activities. A
serious AE (SAE) was defined as any medical occurrence
or effect that was life-threatening, required hospitalization
or prolongation of hospitalization, resulted in persistent or
significant disability or incapacity, resulted in death, con-
genital abnormalities or birth defect, or any other event
judged medically important.
The patients came back to the clinic after 1–3 months
[visit 2 (V2)] for a new prescription, depending on whether
30 or 100 tablets of grass AIT had been prescribed. At V2
the physician interviewed the patients about AEs that
occurred between V1 and V2 during home treatment and
recorded all AEs in the CRF, including his assessment.
Furthermore, the overall compliance of the patient during
the observation period was assessed by the physician
according to overall compliance rates of\50, 50 to\80 or
C80 %: with a rate of C80 % the patient was considered to
be compliant with grass AIT. Symptoms and medication
after 1–3 months of treatment with grass AIT were recor-
ded and compared with data obtained at V1 and the well-
being of the patient with grass AIT compared with previous
years (much better/better/unchanged/worse/much worse)
was assessed. Patients and physicians rated their satisfac-
tion with grass AIT (very satisfied/satisfied/unsatisfied/very
unsatisfied) and globally assessed the tolerability (very
good/good/moderate/poor) and overall effectiveness of
therapy (very good/good/moderate/no effect/not assess-
able). Finally, the continuation or discontinuation of
treatment and its reasons were recorded.
2.4 Statistical Methods
In order to investigate tolerability, the aim was to include at
least 600 patients to be able to detect an ADR with an
incidence of 1 % with a 99 % probability at least once.
Therefore, the aim was to include about 300 physicians
distributed all over Germany in our study, each recording
data from two to three patients. Statistical analyses were
performed using SAS software, versions 8.2, 9.1.3 and 9.2
(SAS Institute, Cary, NC, USA). The statistical analysis
was performed by descriptive statistical methods using
mean, median, standard deviation and range. Test proce-
dures were not used. In the all-patients-treated set of the
study the patients were classified as ‘‘intra-seasonal’’
(June–August 2010) and ‘‘post-seasonal’’ (September 2010
or later) with respect to their start of treatment and the
respective data presented separately. Reasons for pre-
mature termination were non-compliance, AEs, medical
First administration of grass AIT
V1
June Grass pollen season    August 2010
V2 V2
1-month         or        3-month follow-up 
(depending on prescription of 30 or 100 tablets)
Assessment V1:
• Allergy history
• Adverse events (first administration)
• Patient diary (first 14 days)
• Symptoms/medication in previous grass
pollen season
Assessment V2:
• Adverse events (follow-up period)
• Symptoms/medication in grass pollen season
2010
• Compliance/satisfaction with therapy
• Global assessments (tolerabilty/effectiveness)
Fig. 1 Study diagram. V2 was
between 1 and 3 months after
V1. AIT allergy immunotherapy
tablet, V visit
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reasons, insufficient effectiveness, improvement or other
reason. AEs were coded according to the current version of
the Medical Dictionary for Regulatory Activities (Med-
DRA). AEs and ADRs were displayed for patients and
events. All parameters that had been documented for the
study were evaluated for the number of patients who had




Data for 662 patients from 286 sites who had their first
intake of grass AIT in the clinic and had been treated for
51.6 days on average could be evaluated. In a small pro-
portion of these patients treatment had been started after
the end of the grass pollen season (later than August).
Therefore, patients were stratified according to the start of
treatment into the following subgroups: intra-seasonal start
of treatment (until 31 August 2010, n = 620; 93.7 %) and
post-seasonal start of treatment (after 31 August 2010,
n = 42; 6.3 %). The patients’ demographic data at start of
grass AIT (V1) are summarised in Table 1.
After the first administration in the clinic, 53 patients did
not return for the follow-up visit, but 18 patients sent their
diary to the physician by mail, so 627 patients in total could
be evaluated with respect to the tolerability of the second
and further administrations of grass AIT. Diaries were
evaluable for 510 (77.0 %) patients. The flow of patients
through the study is shown in Fig. 2.
3.2 Safety and Tolerability
During the entire observation period AEs were observed in
345 (52.1 %) of the 662 total patients, and in 320 (51.6 %)
of 620 patients who started grass AIT intra-seasonally and
25 (59.5 %) of 42 patients who started grass AIT post-
season. Data on AEs observed during the study are dis-
played in Table 2.
During first administration of grass AIT, AEs were
recorded in 236 (35.6 %) of the total patients, and in 215
(34.7 %) patients who started grass AIT intra-seasonally
and in 21 (50.0 %) patients who started grass AIT post-
season.
Most AEs were assessed as possibly related to grass AIT
and were, therefore, ADRs. The majority of the reactions
were of mild or moderate intensity. Severe reactions were
recorded in 48 (7.7 %) patients with intra-seasonal start of
grass AIT and in 5 (11.9 %) patients with post-seasonal
start; 10.9 % of patients were treated with medication due
to AEs and 7.7 % discontinued treatment with grass AIT
due to AEs.
Table 1 Patient characteristics
BMI body mass index, AIT
allergy immunotherapy tablet,
SD standard deviation
Parameter Start of treatment Total
Intra-seasonal Post-seasonal
(n = 620) (n = 42) (n = 662)
Median age (years) 29.0 28.5 29.0
Range (years) 5–78 12–64 5–78
Patients \18 years [n (%)] 72 (11.6) 3 (7.1) 75 (11.3)
Sex [n (%)]
Male 297 (47.9) 18 (42.9) 315 (47.6)
Female 323 (52.1) 24 (57.1) 347 (52.4)




564 (91.0) 38 (90.5) 602 (91.0)
Moderate-to-severe eye symptoms 437 (70.4) 31 (73.8) 468 (70.7)
Asthma 148 (23.9) 15 (35.7) 163 (24.6)
Allergy history
Mean duration (±SD) since
diagnosis of grass pollen allergy (years)
6.0 ± 8.8 7.1 ± 8.8 6.1 ± 8.8
History of immunotherapy [n (%)] 153 (24.7) 19 (45.2) 172 (26.0)
Symptomatic medication taken during last season [n (%)]
No 126 (20.4) 10 (24.4) 136 (20.6)
Yes 492 (79.6) 31 (75.6) 523 (79.4)
Mean duration of treatment with AIT (days) 52.5 37.6 51.6
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Throat irritation (21.3 % of patients), paraesthesia oral
(19.9 %), oral pruritus (14.0 %), ear pruritus (10.3 %) and
oedema mouth (6.9 %) were recorded with the highest
frequency; all other AEs were observed in less than 5 % of
patients (Fig. 3).
SAEs were reported in four patients. In two patients the
SAEs were unrelated to treatment (meniscus lesion and
bladder surgery) and in two patients the SAEs were con-
sidered possibly related; both had started grass AIT intra-
seasonally. In a 44-year-old male patient an asthma attack,
dyspnoea, swollen lips and tongue, and loss of voice for
2 h was reported on day 5 of treatment and was treated
with antihistamines, corticosteroids and b-sympathomi-
metics. In a 73-year-old female patient nausea, fainting,
hypotension, bradycardia, diarrhoea, vomiting and stomach
pain for less than 1 day were reported 5 h after first
administration and 1.75 h after dinner. Symptoms disap-
peared within 2 h without treatment. In both patients the
reaction was considered medically important and the
patients discontinued treatment.
The results of the evaluation of the patient diary for the
first 14 days of treatment are shown in Fig. 4. The rate of
AEs recorded by the patients decreased continuously from
44.7 % of patients who recorded AEs on day 1 of treatment
to 26.9 % with AEs on day 14. On average, about 5 % of
patients reported having forgotten to take their daily tablet
during the 14-day diary period.
Global tolerability was assessed as ‘‘good’’ or ‘‘very
good’’ by 519 of 595 patients (87.2 %) and by the physi-
cians in 542 of 593 patients (91.4 %) who had an evaluable
assessment.
3.3 Effectiveness and Treatment Satisfaction
Effectiveness parameters could be evaluated in a total of
586 patients; 551 started treatment with grass AIT intra-
seasonally.
Overall, 77.7 % of patients who started grass AIT intra-
seasonally responded to treatment (as being ‘‘free of
symptoms’’ or ‘‘improved’’) with respect to nasal symp-
toms, 74.8 % with respect to eye symptoms, 66.4 % with
respect to bronchial symptoms, and 69.0 % with respect to
skin symptoms in the grass pollen season with grass AIT
compared with the previous season before grass AIT. The
use of symptomatic medication by patients decreased from
First administration of grass AIT n=662
• Intra-seasonal n=620
• Post-seasonal n=  42
Discontinued n=130 (19.6%)
• Non-compliance n=  67 (10.1%)
• Adverse events n=  51 (  7.7%)
• Medical reasons n=    4 (  0.6%)
• Insufficient effectiveness n=    3 (  0.5%)
• Improvement n=    2 (  0.3%)
• Other reasons n=    3 (  0.5%)
Grass AIT continued at end of study n= 532 (80.4%)
Fig. 2 Flow of patients. AIT allergy immunotherapy tablet
Table 2 Adverse events and
adverse drug reactions in all
patients treated
ADR adverse drug reaction,
AE adverse event, E number of
events, n number of patients,
SAE serious adverse event
Parameter Start of treatment Total
Intra-seasonal Post-seasonal
(n = 620) (n = 42) (n = 662)
Patients analysed [n (%)]
With first administration in the clinic 620 (100.0) 42 (100.0) 662 (100.0)
With [1 day of treatment 586 (94.5) 41 (97.6) 627 (94.7)
With evaluable diaries 478 (77.1) 32 (76.2) 510 (77.0)
AEs [n (%), E]
On first treatment day 215 (34.7), 433 21 (50.0), 48 236 (35.6), 481
During entire course of treatment 320 (51.6), 1,745 25 (59.5), 185 345 (52.1), 1,930
Treated 69 (11.1), 248 3 (7.1), 12 72 (10.9), 260
Leading to discontinuation 46 (7.4), 122 5 (11.9), 22 51 (7.7), 144
Intensity of AEs [n (%), E]
Mild 202 (32.6), 1,247 14 (33.3), 133 216 (32.6), 1,380
Moderate 57 (9.2), 230 6 (14.3), 33 63 (9.5), 263
Severe 48 (7.7), 150 5 (11.9), 11 53 (8.0), 161
Missing values 13 (2.1), 118 – 13 (2.0), 126
SAEs [n (%), E] 4 (0.6), 14 – 4 (0.6), 14
ADRs [n (%), E] 305 (49.2), 1,654 25 (59.5), 174 330 (49.8), 1,828
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79.8 % in the previous season to 40.6 % in the season with
grass AIT. Well-being was assessed to be ‘‘better’’ or
‘‘much better’’ by 67.4 % of patients who started grass AIT
intra-seasonally. More than 90 % of patients and physi-
cians were ‘‘satisfied’’ or ‘‘very satisfied’’ with treatment
for patients who started grass AIT intra-seasonally. The
global effectiveness of treatment was assessed as ‘‘very
good’’ or ‘‘good’’ by 355 of 436 patients (81.4 %) and by
the physicians in 386 of 450 (85.8 %) patients.
4 Discussion
This study was planned to evaluate tolerability of an intra-
seasonal start of treatment with grass AIT under real-life
conditions. The prospective, open-label, observational
design was appropriate to record data on the routine use of
AIT in a real-life setting.
In this study data were recorded on 662 patients with
moderate to severe rhinoconjunctivitis (including 24.6 %
with additional asthma) who were routinely treated with
grass AIT by practising allergists. Treatment with grass
AIT was started by a first administration of the tablet in the
clinic in 620 patients within the grass pollen season
(between June and August 2010 in Germany) and in 42
patients post-seasonally after the end of August (when the
grass pollen season in Germany is over). Since the patients
had not been randomly allocated to intra- or extra-seasonal
start of grass AIT and the overall duration of treatment was
shorter in patients who started grass AIT post-seasonally
than in patients who started grass AIT within season, and
due to the small number of patients with a post-seasonal
start, the rates of AEs can only be compared between the
two groups with limitations.
Patients were asked to enter their daily administration of
grass AIT and all AEs observed in a diary for the first 14
days of treatment. The frequency of AEs recorded in the
diaries was highest on day 1 of treatment and declined
considerably over the course of the first 14 days of treat-
ment (44.7 % of patients with AEs on day 1, 26.9 % on day
14), as was expected from the results of the controlled
clinical trials with grass AIT [6–13]. The majority of
patients were compliant with daily administration of the
tablet; on average, only 5 % forgot to take their tablet
according to the diary recordings.
At first administration of grass AIT under supervision in
the clinic within the grass pollen season, AEs were recor-
ded in 34.7 % of patients and were recorded in 51.6 % for
the entire observation period of an average 52.5 days. Most
of the reactions observed in our study were of mild to
moderate intensity and were severe in 8.0 % of all patients
treated. In two patients with an intra-seasonal start, grass
AIT was discontinued due to an SAE. The most frequent
reactions were local reactions at the application site in the
mouth, such as throat irritation, oral paraesthesia, oral
pruritus, ear pruritus and mouth oedema. This profile of
reactions corresponds to the known safety profile from
controlled clinical trials, as described in the Summary of
Product Characteristics for GRAZAX. Therefore, our
study confirms the tolerability profile of an intra-seasonal
start of grass AIT as observed in the previous placebo-
controlled clinical trial [17].
Limitations of the study are those of a prospective,
open-label, uncontrolled observational study. In order to
minimise a potential investigator bias, sites were involved
across Germany that were selected from random regional
lists of allergists according to their willingness to partici-
pate. For reduction of a potential selection bias, physicians
were asked to include patients in consecutive order







Fig. 3 Safety profile of grass allergy immunotherapy tablet in all
patients treated during the entire treatment period. Data are the
percentage of patients with adverse events observed in C5 % of
















AE Forgotten to take grass AIT
Fig. 4 Patient diary data. Data are the percentage of patients who
recorded adverse events and the percentage of patients who recorded
that they have forgotten to take grass allergy immunotherapy tablets
over the first 14 days of treatment. AE adverse event, AIT allergy
immunotherapy tablet
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according to the patients consenting to be included in the
study.
Due to the short period of treatment and the start of
treatment within the grass pollen season, the reliability of
data on effectiveness in terms of the improvement of
symptoms and use of medication compared with the pre-
vious season before initiation of grass AIT is very limited
and possibly biased by previous season grass pollen load
and placebo effect. Nevertheless, a considerable proportion
of patients considered their well-being to be already
improved during the grass pollen season in which grass
AIT was initiated and the rate of satisfaction with treatment
was higher than 90 %. This is in agreement with the early
immunological effects of treatment reported by Reich et al.
[17], suggesting an early effect that may already be per-
ceived by the patient during the grass pollen season in
which treatment was started. Changes from baseline in
concentrations of IgE-blocking factor were significantly
greater in the grass AIT-treated group than with placebo
after about 9 weeks of treatment. The authors suggested
that an immunomodulatory effect appears within a short
period of treatment. Thus, their study results [17] were
consistent with previously reported clinical trials, which
show that the immunological response to grass AIT may
occur early in treatment and is likely to be unaffected by
the time of treatment initiation relative to the grass pollen
season [6, 10, 13–15].
An evaluation of the data pooled from several trials with
pre-seasonal initiation of grass AIT revealed that symptom
and medication scores were significantly reduced versus
placebo if the treatment period was initiated at least
8 weeks prior to the expected start of the grass pollen
season, and the difference from placebo was increased if
the pre-seasonal treatment period was 16 weeks, suggest-
ing that the improvement of clinical symptoms with an
intra-seasonal start in the same grass pollen season is
limited [19].
In a recent analysis of immunological data from a
clinical trial with subcutaneous immunotherapy, a modest
but significant inverse relationship was demonstrated
between post-immunotherapy serum inhibitory activity and
combined symptom-rescue medication scores, whereas no
such observation was made for immune-reactive IgG4
levels. This suggests that the increase of IgE-blocking
factor may predict a reduction of clinical symptoms [20].
5 Conclusion
In this non-interventional, observational study the intra-
seasonal start of grass AIT during routine treatment was
well-tolerated, confirming the data from a previous pla-
cebo-controlled clinical trial. Our data suggest that grass
AIT can be initiated within the season without compro-
mising safety and tolerability, allowing for an immediate
treatment start with SIT when the patient presents with the
allergic complaints.
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